Astellas Pharma (TSE:4503) 3-Year EPS without NRI Growth Rate

: -19.60% (As of Dec. 2023)

View and export this data going back to 1949. Start your Free Trial

Astellas Pharma's EPS without NRI for the three months ended in Dec. 2023 was 円7.91.

During the past 12 months, Astellas Pharma's average EPS without NRI Growth Rate was -105.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was -19.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -12.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Astellas Pharma was 89.70% per year. The lowest was -52.80% per year. And the median was 7.50% per year.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma 3-Year EPS without NRI Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's 3-Year EPS without NRI Growth Rate falls into.

Astellas Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Astellas Pharma (TSE:4503) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Astellas Pharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (TSE:4503) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

ALPMY:USA ALPMF:USA 4503:Mexico YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (TSE:4503) Headlines

No Headlines